DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lflrxx/global) has announced the addition of the "Global Neurostimulation Devices Market 2015" report to their offering.
The analysts forecast the global neurostimulation devices market to grow at a CAGR of 5.37% over the period 2014-2019.
The report, Global Neurostimulation Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the global neurostimulation devices market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Major companies are developing advanced neurostimulation devices for more efficient, less-invasive or non-invasive neuromodulation treatment of people with disorders. For instance, Prodigy developed by St. Jude Medical is used to treat individuals with chronic pain. It is the first neuromodulation system that offers alternate stimulation waveforms for chronic pain management. The new burst stimulation technology can also be used to treat chronic pain that may not be fully managed by conventional tonic stimulation.
According to the report, about 203 million people across the world have mental disorders. Changing lifestyles, social pressure, and stressful life events can lead to a range of disorders, including mood swings and anxiety. In some cases, problems in communities or cultures, poverty, unemployment, poor nutrition, relationship issues, and migration can cause mental disorders. Neurostimulation devices, with their advanced, less-invasive techniques, are gradually becoming the best alternative to treat such types of disease. These devices are the standard form of care for migraine, Parkinson's disease, depression, angina, obsessive-compulsive disorder, traumatic brain injuries, and obesity.
Further, the report states that the introduction of improved drug delivery techniques, enhanced drug pipelines, and the launch of novel monoclonal antibody molecules for the treatment of neurological disorders restrict market growth.
- Boston Scientific
- St. Jude Medical
Other Prominent Vendors
- Aleva Neurotherapeutics
- Autonomic Technologies
- ImThera Medical
- Inspire Medical Systems
- Neuros Medical
- SPR Therapeutics
- Synapse Biomedical
For more information visit http://www.researchandmarkets.com/research/lflrxx/global